Global Plasma Protein Therapeutics Market By Product (Immunoglobulin, Albumin, Plasma Derived Clotting Factor, Fibrinogen, Others), By Application (Hemophilia, Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura (ITP), Others), By End User (Hospitals, Research Laboratories and Institutions, Stand-Alone Blood Banks, Others), By Region, Competition Forecast & Opportunities, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 33.26 Billion
CAGR (2026-2031)	6.77%
Fastest Growing Segment	Immunoglobulin
Largest Market	Asia Pacific
Market Size (2031)	USD 49.27 Billion

Market Overview

The Global Plasma Protein Therapeutics Market will grow from USD 33.26 Billion in 2025 to USD 49.27 Billion by 2031 at a 6.77% CAGR. Plasma protein therapeutics are biologic medicines derived from the fractionation of human blood plasma, designed to treat rare, chronic, and life-threatening conditions such as primary immunodeficiencies and hemophilia. The market is fundamentally driven by the increasing diagnosis of immunologic and neurologic disorders requiring lifelong replacement therapies, alongside an aging global population that demands sustained medical intervention. Furthermore, advancements in diagnostic technologies are continually expanding the identifiable patient pool, necessitating consistent production increases distinct from temporary consumption trends.

A significant challenge impeding broader market expansion is the complexity of maintaining a resilient supply chain, which currently relies heavily on a limited number of geographic regions for raw material collection. This reliance creates vulnerability to regulatory changes or logistical disruptions that can threaten global availability. According to the Plasma Protein Therapeutics Association, in 2025, North American donors provided over 63% of the global plasma supply utilized for manufacturing. Consequently, achieving regional self-sufficiency remains a critical hurdle for stabilizing the market and meeting the rising international demand.

Key Market Drivers

Surging Global Demand for Immunoglobulin Therapies is acting as a primary catalyst for market growth, fundamentally driven by the expanding administration of immunoglobulins (IG) for primary and secondary immunodeficiencies. As diagnostic rates improve and clinical applications extend to neurological conditions like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), patient reliance on these lifelong therapies has intensified. Manufacturers are witnessing robust uptake in both subcutaneous and intravenous formulations, necessitating higher output to prevent shortages and meet the needs of an expanding patient base. According to CSL Limited, February 2025, in the 'Half Year Results 2025', the company’s immunoglobulin portfolio generated sales of $3.17 billion, representing a 15% increase compared to the previous corresponding period. This trend underscores the critical role of IG products in sustaining the financial and operational expansion of major market players.

The Expansion of Global Plasma Collection Infrastructure is equally critical, as the industry scales operations to secure the raw material required for fractionation. Companies are heavily investing in extending their donor center networks and optimizing supply chain logistics to mitigate the risks of regional dependency and enhance collection yields. This structural growth is essential for stabilizing the volume of plasma available for manufacturing therapies such as albumin and coagulation factors. According to Forbes, February 2025, in the article 'Inside Takeda's Plasma-Derived Therapy Ecosystem', Takeda alone now collects more than 15 million liters of plasma annually to support its production needs. Furthermore, the overall market trajectory remains positive; according to Grifols, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', the company reported total annual revenues of €7.2 billion, reflecting the sector's continued financial resilience.

Download Free Sample Report

Key Market Challenges

The fundamental challenge restricting the Global Plasma Protein Therapeutics Market is the fragility of its supply chain, characterized by an extreme reliance on a limited number of geographic regions for source plasma collection. This concentrated dependency creates a precarious bottleneck where global availability is disproportionately tethered to the operational stability of a single region. Consequently, any logistical disruption or localized policy shift in this primary source area can trigger worldwide shortages, preventing manufacturers from scaling production to consistently meet the rising demand for life-saving therapies.

The severity of this infrastructure imbalance is severely hampering the industry's ability to diversify its raw material sources. According to the Plasma Protein Therapeutics Association, in 2024, the collection landscape was so skewed that the state of Texas alone operated 178 plasma centers, surpassing the 177 centers located across the entire European continent. This stark disparity underscores the market's vulnerability to regional constraints. As long as collection capacity remains so geographically confined, the industry cannot achieve the resilient supply volume necessary to support sustained global market expansion.

Key Market Trends

The Transition to Subcutaneous Immunoglobulin Administration is fundamentally reshaping the market by shifting treatment paradigms from clinical settings to flexible home-based care. This trend is propelled by the development of high-concentration formulations that allow patients with primary immunodeficiencies to self-administer therapies, significantly improving quality of life while reducing the logistical burden on hospitals. The preference for these convenient dosing regimens is generating distinct growth within the immunoglobulin segment, outpacing traditional intravenous methods as manufacturers introduce user-friendly delivery systems. According to CSL Limited, February 2025, in the 'Half Year Results 2025', sales of the subcutaneous product HIZENTRA increased by 16% compared to the previous period, driven specifically by the strong market uptake of pre-filled syringe options.

Concurrently, the Adoption of Advanced Chromatographic Fractionation Techniques is becoming a pivotal trend as manufacturers seek to maximize protein yield from every liter of collected plasma. Facing high raw material costs, companies are aggressively implementing automated purification processes to enhance the recovery rates of valuable proteins, essentially decoupling production volume from linear collection growth. This strategic focus on operational efficiency is enabling producers to lower the cost per gram of protein and improve profitability despite volatile donor markets. According to Grifols, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', the company achieved an Adjusted EBITDA margin of 26.6% in the fourth quarter, a performance primarily attributed to continuous yield improvements and the successful execution of its operational optimization plan.

Segmental Insights

The Immunoglobulin segment currently stands as the fastest-growing category within the Global Plasma Protein Therapeutics Market, driven largely by the rising diagnosis of primary and secondary immunodeficiency disorders. This expansion is further supported by the increasing adoption of immunoglobulin replacement therapies for various autoimmune and neurological conditions. Additionally, regulatory bodies such as the U.S. Food and Drug Administration have approved expanded indications and novel subcutaneous administration methods, thereby improving patient accessibility and compliance. These factors collectively ensure sustained demand and prioritize immunoglobulins as a critical driver of overall market development.

Regional Insights

Asia Pacific stands out as the leading region in the Global Plasma Protein Therapeutics Market, driven primarily by its vast and rapidly aging population which creates a substantial patient base for critical treatments. The region’s dominance is largely anchored by the exceptional demand for albumin, particularly in China, which represents the largest consumer market for this specific protein globally. Furthermore, improving diagnostic capabilities for rare diseases like hemophilia and primary immunodeficiency are unlocking significant unmet needs. Governments across the region are also actively expanding domestic plasma fractionation infrastructure to secure local supply, solidifying Asia Pacific’s pivotal position in the global landscape.

Recent Developments

• In November 2025, CSL Behring announced a capital investment of $1.5 billion to enhance its plasma supply chain and manufacturing infrastructure within the United States. This strategic initiative was designed to address the growing long-term clinical demand for immunoglobulin and other plasma-derived therapies. The expansion aimed to strengthen the company's production footprint and secure a reliable supply of these critical medicines for patients. The company indicated that the investment would create hundreds of new jobs and support the continued growth of its portfolio in the expanding global market for plasma protein therapeutics.
• In September 2025, Takeda Pharmaceutical Company Limited reaffirmed its strategic commitment to expanding its manufacturing capacity for plasma-derived therapies by updating its construction plans for a new facility in Juso, Osaka. The company revised the project's total investment to 153 billion yen to address rising construction costs and evolving market conditions. This state-of-the-art plant aims to ensure a stable and sustainable global supply of essential plasma treatments. The facility's design and timeline were reevaluated to maximize long-term benefits for patients and the healthcare system, with a targeted completion date set for fiscal year 2029.
• In September 2024, Octapharma USA, Inc. received expanded approval from the U.S. Food and Drug Administration for fibryga, a fibrinogen concentrate. The regulatory body authorized the product for the treatment of bleeding patients with acquired fibrinogen deficiency, making it the first virus-inactivated, human plasma-derived fibrinogen concentrate approved for this specific indication. This development provided healthcare professionals with a rapid and precise alternative to cryoprecipitate for managing severe bleeding episodes in surgical and emergency settings. The approval was described as a significant advancement in establishing a new standard of care for hemostasis management in the critical care environment.
• In July 2024, GC Biopharma Corp. announced the initial shipment of its immunoglobulin blood product, Alyglo, to the United States market. This milestone followed the U.S. Food and Drug Administration's approval of the therapy for the treatment of primary humoral immunodeficiency. The company secured a strategic partnership with a major pharmacy benefit manager to list the product on formularies and established contracts with specialty pharmacies to ensure a robust distribution network. This launch marked a significant expansion for the company into the world's largest immunoglobulin market, aiming to capture market share through its vertical integration of plasma collection and production capabilities.

Key Market Players

• Grifols, S.A.
• CSL Behring AG
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxalta Incorporated
• Kedrion S.p.A.
• LFB S.A.
• Bio Products Laboratory Ltd.
• Shanghai RAAS Blood Products Co., Ltd.
• Haema AG

By Product	By Application	By End User	By Region
Immunoglobulin Albumin Plasma Derived Clotting Factor Fibrinogen Others	Hemophilia Primary Immunodeficiency Disorder (PID) Idiopathic Thrombocytopenic Purpura (ITP) Others	Hospitals Research Laboratories and Institutions Stand-Alone Blood Banks Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Plasma Protein Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Plasma Protein Therapeutics Market, By Product:

• Immunoglobulin
• Albumin
• Plasma Derived Clotting Factor
• Fibrinogen
• Others

• Plasma Protein Therapeutics Market, By Application:

• Hemophilia
• Primary Immunodeficiency Disorder (PID)
• Idiopathic Thrombocytopenic Purpura (ITP)
• Others

• Plasma Protein Therapeutics Market, By End User:

• Hospitals
• Research Laboratories and Institutions
• Stand-Alone Blood Banks
• Others

• Plasma Protein Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE